TickerFacts.

RxSight, Inc. (RXST): Cash & Equivalents

Annual figures by period end, from SEC filings.

$19.95M
As of 2025-12-31
$13.35M
As of 2026-06-30
+19.0%
3-year compound annual growth
+7.3%
5-year compound annual growth
$24.36M2020-12-31: $13.99M2021-12-31: $24.36M2022-12-31: $11.83M2023-12-31: $9.69M2024-12-31: $16.71M2025-12-31: $19.95M$19.95M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$19.95M+19.4%2026-02-25, Balance as of period end
2024-12-31$16.71M+72.4%2026-02-25, Balance as of period end
2023-12-31$9.69M-18.1%2025-02-25, Balance as of period end
2022-12-31$11.83M-51.4%2024-02-28, Balance as of period end
2021-12-31$24.36M+74.1%2023-03-06, Balance as of period end
2020-12-31$13.99Mn/a2022-03-08, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Ophthalmic Goods), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
RxSight, Inc. (RXST)2025-12-31$19.95M+19.4%
Staar Surgical Co (STAA)2026-01-02$153.15M+6.2%
Warby Parker Inc. (WRBY)2025-12-31$286.36M+12.7%
National Vision Holdings, Inc. (EYE)2026-01-03$38.71M-47.7%
Cooper Companies, Inc. (COO)2025-10-31$110.60M+2.8%
Bausch & Lomb Corp (BLCO)2025-12-31$383.00M+25.6%
Innovative Eyewear Inc (LUCY)2025-12-31$6.51M+147.7%

Compare RXST, STAA, WRBY, EYE side by side · Screen every company in Ophthalmic Goods ↗